Allogene Therapeutics, Inc. (ALLO) Stock Analysis

Allogene (ALLO) Q2 2026 Earnings Call Transcript

Wed, August 19, 2026 at 8:58 PM UTC 4 min read

Allogene (ALLO) reported its Q2 2026 earnings, highlighting a significant increase in research and development expenses due to ongoing clinical trials for its CAR T-cell therapies. The company also announced promising interim data from its ongoing studies, which could enhance its competitive position in the immunotherapy market. For investors, these developments may indicate potential future revenue growth, but the rising costs also warrant close monitoring of the company's financial health.

Read full article →

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Thu, August 13, 2026 at 5:47 PM UTC 3 min read

Allogene Therapeutics reported its Q2 earnings, surpassing analysts' expectations primarily due to reduced research and development costs. This performance highlights the company's ability to manage expenses effectively while progressing in its clinical programs, which could enhance investor confidence. The positive earnings surprise may also indicate a more sustainable financial outlook, making ALLO an attractive option for investors looking for growth potential in the biotech sector.

Read full article →